Facebook Facebook Share
Posted by Target Ovarian Cancer on Monday 2 February 2009

Target Ovarian Cancer today announced the members of the independent advisory panel who are overseeing the groundbreaking Target Ovarian Cancer Pathfinder Study. They include patient and relative representation in addition to a wide range of senior healthcare professionals and researchers involved in diagnosing, treating and caring for women with ovarian cancer.

Designed to provide the most comprehensive information on the experiences of those living or working with ovarian cancer in the UK, the study will identify opportunities to make progress in improving survival and quality of life for the 6,800 women diagnosed each year with the disease.

It is a long term study, and ongoing results will be made available to all those interested in improving the outlook for women, and will help inform the activities of the charity, to ensure that money it invests is used in areas of identified need, and where it is felt it will add significant value.

"We have been delighted at the willingness of some very senior people to become involved", said Target Ovarian Cancer Chief Executive Annwen Jones. "It reflects the fact they recognise we can do more for the women diagnosed with this disease, and that we need to work together to bring about improvement. In the past, efforts have been largely fragmented and levels of investment very low. It is time for that to change."

Professor Sir Kenneth Calman, PhD MD FRCS FRCP who is the Chair of the National Cancer Research Institute has recently become the first Patron of Target Ovarian Cancer. He welcomes the approach of the charity in tackling these major issues. "Ovarian cancer is the fourth most common cancer in women with low survival rates that have changed little over the past 20 years. There is so much that can be done to improve this situation and to give women with ovarian cancer across the UK the highest possible quality of life. I applaud Target Ovarian Cancer for its strategic approach to understanding and tackling this disease, through the Pathfinder Study, and for providing substantial new funds to combat this disease."

Target Ovarian Cancer commissioned research agency Synovate to carry out initial qualitative work amongst women, nurses, clinicians and researchers from around the UK, establishing the range of views and ideas. This will help the panel establish the scope of the study, which will track progress over a number of years.

Advisory Panel members

Chairman: Professor Robert Haward
Emeritus Professor of Cancer Studies, University of Leeds
Associate Director, National Cancer Research Network

Dr James Brenton
Cambridge Research Institute, University of Cambridge

Professor Hilary Calvert
Clinical Director, Northern Cancer Research Institute, University of Newcastle

Dr Willie Hamilton
Academic GP, University of Bristol

Professor Jonathan Ledermann
Chairman, National Cancer Research Institute Gynaecology Group
University College London

Professor David Luesley
President, British Gynaecological Cancer Society
University of Birmingham

Professor Glenn McCluggage
President, British Association of Gynaecological Pathologists
University of Belfast

Dr Andy Nordin
Clinical Advisor for Gynaecology to the NHS Cancer Improvement Team and Cancer Action Team. East Kent Hospitals University Trust

Mrs Lisa Peck
Interim and Past President, National Forum of Gynaecological Oncology Nurses
Gloucestershire Oncology Centre, Three Counties Cancer Network

Sandra Woodward Patient advocate

Lindy Waldron Patient advocate

Howard Webber Relative advocate

Joanna Barker
Chairman of the Board of Trustees, Target Ovarian Cancer

Annwen Jones
Chief Executive Officer, Target Ovarian Cancer